The approval of Casgevy in late 2023 marked a historic milestone in modern medicine. As the first CRISPR-based gene editing therapy to gain regulatory approval, it moved gene editing from theoretical promise to clinical reality. This moment not only validated decades of research but also signaled to investors and clinicians that gene editing had reached a critical turning point.
Casgevy, approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), produced compelling clinical results. In trials, 97% of SCD patients avoided vaso-occlusive crises for at least 12 months, while more than 90% of TDT patients achieved transfusion independence. Although the treatment process remains complex, its success validated years of research and established an important proof point for the field.
Today, gene editing extends far beyond a single therapy. The field now includes over 480 programs spanning four modalities: nuclease editing, DNA base editing, DNA writing, and RNA editing. These approaches target a wide array of diseases, from inherited disorders to infectious diseases and more, reflecting the vast potential of gene editing across medicine.
Programs are advancing in areas such as hemophilia, Duchenne muscular dystrophy, Wilson's disease, alpha-1 antitrypsin deficiency, and other rare disorders. Researchers are also expanding into larger markets. Early studies in cardiovascular disease, for example, have demonstrated meaningful reductions in cholesterol and triglyceride levels, highlighting the potential for gene editing to address some of the most prevalent chronic conditions.
Gene editing is also being explored for conditions beyond inherited diseases, including hepatitis B, HIV, eye infections, and drug-resistant bacterial infections.
A major shift in gene editing is moving from editing cells outside the body to delivering treatments directly inside the body. New delivery tools could make therapies simpler, less costly, and easier to use across more diseases.
Gene editing has evolved from a promising scientific concept into a growing therapeutic reality. While Casgevy provided the field's first commercial validation, the next phase of growth will likely be driven by new editing technologies, improved delivery platforms, and expansion into larger disease categories. As more late-stage programs advance, gene editing appears increasingly well-positioned to become an important part of the future treatment landscape.
For more information on related investment opportunities and insights, read DECODER – CRISPR and Sharper: Gene Editing Technologies Shaping the Next Generation of Therapeutics, published on April 1, 2026, by Myles Minter, Ph.D., partner, and equity research analyst for the biotech sector.